BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

Leukemia, Myeloid, Chronic-phase Clinical Trial

Official title:
Phase I Study of BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

Status Completed

Clinical Trial Summary

The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesylate (Gleevec).

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Blast Crisis
Leukemia
Leukemia, Lymphoblastic, Acute, Philadelphia-positive
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Chronic-Phase
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT00103701
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase	Phase 1
Start date	November 2003
Completion date	March 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01725204` - Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia	Phase 2
Completed	`NCT01856283` - Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells	Phase 2
Completed	`NCT00048672` - Therapy of Early Chronic Phase CML With Gleevec	Phase 2
Recruiting	`NCT02767063` - Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)	Phase 1/Phase 2
Terminated	`NCT01827930` - Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response	Phase 3
Terminated	`NCT01488253` - Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants	Phase 2
Withdrawn	`NCT01650467` - Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms	N/A
Completed	`NCT02888964` - Pioglityazone and Imatinib for CML Patients	Phase 2
Active, not recruiting	`NCT03239886` - Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log	N/A
Terminated	`NCT03807479` - Study in Patients With Chronic Leukemia	Phase 2